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Edited by Ned ManteiAbstract Adrenomedullin is a peptide found in a variety of cells
and tissues and involved in a multitude of biological processes.
Recently, adrenomedullin has been identiﬁed as a host defense
peptide and as such it plays a role in the inﬂammatory response.
The transcription factor NF-jB is a major regulator of genes
involved in the inﬂammatory response and the aim of this study
was to determine whether NF-jB played a role in the inﬂam-
matory process triggered by adrenomedullin. Skin epithelial cells
(HaCaTs) were used as our model in vitro. Western blot analysis
from adrenomedullin-stimulated HaCaT cells revealed a rapid
degradation of NF-jB inhibitor a and b followed by the
translocation of free NF-jB to the nucleus, where it was
detected by Texas Red immunostaining after incubation with
adrenomedullin for 15 min. Electromobility shift assay showed
that NF-jB present in the nucleus was active, since it bound to a
probe containing an NF-jB binding site. Supershift assays
indicated that p50 and p65, members of the NF-jB family, were
both part of the NF-jB dimmers involved in adrenomedullin cell
signaling. HaCaTs secreted interleukin-6 in response to AM,
which was signiﬁcantly attenuated by the NF-jB inhibitor SN-
50. Taken together, the data lend support for an immunoregu-
latory role for AM.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Adrenomedullin (AM) is a multifunctional peptide ﬁrst iso-
lated from extracts of human phaeochromocytoma and noted,
primarily, for its potent vasorelaxant eﬀects [1]. The 52 amino
acid peptide is produced by a wide variety of cells and tissues,
amongst which the endothelium is prominent [2]. Recently,
studies from our laboratory, and others, have noted that AM is
also expressed in key mucosal surfaces and is emerging as an
important eﬀector molecule in mucosal defense [3–7].
AM is found in low picomolar concentrations in the circu-
lation and is reported to increase in a variety of disorders in-
cluding sepsis, congestive failure, renal failure and
hypertension for review see [2] and references within. AM has
been demonstrated to accumulate in the apical regions of
normal bronchial epithelium, and in the gut, skin and oral
mucosa [6–10]. Cameron and Fleming [11] demonstrated the
localization of AM mRNA in epithelial cells lining the uterus,* Corresponding author. Fax: +44-20-7882-7153.
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doi:10.1016/j.febslet.2004.10.019bronchioles and gastrointestinal tract in rodents. It has also
been demonstrated that AM is expressed throughout all epi-
thelial components of normal and malignant human skin
[6,12]. Data from our laboratory, and others, implicate AM as
a possible growth regulatory factor of the skin and contributes
as an antimicrobial agent in the integument’s protective barrier
[3,5,6,10,12,13].
The recorded activities of some antimicrobial peptides ex-
tend beyond antimicrobial action to functions indicating roles
in regulating host defense mechanisms. Most activities are in-
volved in modulating/enhancing the inﬂammatory response. A
key example of this is the observation that AM can stimulate
the release of proinﬂammatory cytokines such as interleukin
(IL)-6 from ﬁbroblasts [14]. Studies from our own laboratory
have shown that AM can increase expression of cell adhesion
molecules such as ICAM-1 and E-selectin and this may be
mediated via an NF-jB-dependent mechanism [15–17].
The ubiquitously expressed transcription factor nuclear
factor jB (NF-jB) is a key player in the regulation of immune
and inﬂammatory responses, including those of proinﬂam-
matory cytokines and AM [18,19], and numerous ﬁndings have
indicated that NF-jB also plays a pivotal role in epidermal
biology. The translocation and activation of NF-jB in re-
sponse to various stimuli, such as LPS and cytokine, occur at
the molecular level. In its inactive state, the heterodimeric NF-
jB, which is mainly composed of 2 subunits p50 (NF-jB1) and
p65 (Rel A), is present in the cytosol associated with its in-
hibitor protein Ij-B [20]. Upon stimulation, Ij-B undergoes
phosphorylation, thereby unmasking the nuclear localization
signal on the p65 subunit and allowing the nuclear transloca-
tion of the complex [21].
We, and other workers, have reported the eﬀects of AM on
epidermal cells in relation to its eﬀect on cell proliferation and
its secretion in response to a range of agents, such as cytokines
and steroids [6,10]. We also know that AM has immuno-
modulatory eﬀects in keratinocytes [17] and taken together it is
tempting to suggest that under some conditions AM can di-
rectly couple to a signaling pathway relevant to keratinocyte
function, in particular hyperproliferation and inﬂammatory
mediator production. The aim of this study was to determine
whether AM exerts its inﬂammatory role in keratinocytes
through the activation of NF-jB and IL-6 secretion.2. Materials and methods
2.1. Materials
Human adrenomedullin peptide was purchased from Phoenix Eu-
rope GmbH (Germany). HaCaT cells were used throughout andblished by Elsevier B.V. All rights reserved.
Fig. 1. Eﬀect of AM on IjBa=b degradation. Protein was extracted
from HaCaT cells treated with 107 M of AM for various lengths of
time and immunoblotted for IjBa, IjBb or actin. (A) Upper panel is a
representative Western blot image of IjBa levels; middle panel is an
image of IjBb levels; lower panel is a representative Western blot
image of actin levels. (B) Quantiﬁcation of pooled data from three
experiments; open squares represent IBa levels, ﬁlled squares IjBb
levels. Values are means S.E.M., n ¼ 3. **P < 0:05, ***P < 0:01
compared to control (Tukey’s multiple comparison test).
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transformation [22]. These cells were a generous gift from Professor N.
Fusenig (Heidelberg, Germany). HeLa cell nuclear extracts were used
as a positive control for the supershift assays and were obtained from
Promega (UK). DMEM and all supplements were obtained from In-
vitrogen (Paisley, UK). Lipopolysaccharide (LPS; E. coli serotype
O26:B6) was from Sigma–Aldrich (Dorset, UK). Interleukin-6 ELISA
kit was purchased from R&D Europe Systems (Oxon, UK). IjBa,
IjBb, NF-jB-p50 and -p65 antibodies, Texas Red and secondary an-
tibody goat anti-rabbit were purchased from Santa Cruz Biotechnol-
ogies (Autogen Bioclear, Calne, UK). The ECL kit and Hyperﬁlm for
Western blotting was obtained from Amersham Biosciences (Amer-
sham, UK). The gel shift assay core system and oligonucleotides for
NF-jB and SP1 were from Promega. All other chemicals were of the
best grade available and obtained from Sigma–Aldrich.
2.2. Cell culture and treatments
HaCaT cells were in DMEM supplemented with 10% fetal bovine
serum (FBS) and routine antibiotics in a humidiﬁed atmosphere con-
taining 5% CO2 and 95% air at 37 C. Twenty-four hours before ex-
periments were carried out, 80% conﬂuent 60  15 mm tissue culture
dishes were rendered quiescent by placing them in serum-free medium.
On the day of experiments, cells were washed in sterile PBS and in-
cubated with adrenomedullin at a ﬁnal concentration of 108–107 M
or LPS at 10 ng/ml to 1 lg/ml.
In other experiments, cells were treated with 108 M AM for 4 h in
the absence or presence of 105 M SN-50 a speciﬁc NF-jB Inhibitor
[52]. After this time, culture supernatants were harvested and stored at
)20 C until ready for assay. IL-6 was measured by ELISA.
2.3. Western blotting
After treatment cells were lysed by adding 0.5 ml of 1· SDS–PAGE
sample buﬀer (2% SDS, 10% glycerol, and 5% 2-mercaptoethanol,
0.002% bromophenol blue, and 62.5 mM Tris–HCl, pH 6.8). Twenty ll
of cell lysate was separated on a 12% SDS–PAGE gel. The proteins
were then transferred to a PVDF membrane that was blocked over-
night with PBS-Tween (PBS-T) containing 5% dried skimmed milk
(PBS-TM). The membrane was then incubated with the primary an-
tibodies against IjBa and b for 2 h at 1:1000 dilution in PBS-TM at
room temperature and after 3 · 5 min washes in PBS-T, the membrane
was incubated with the secondary antibody (goat anti-rabbit) for 1h at
1:2000 dilution in PBS-TM at room temperature. After 3 · 5 min
washes in PBS-T, ECL reaction was performed following the manu-
facturer’s instructions. Membranes were exposed to X-ray Hyperﬁlm
ECL.
2.4. Electrophoretic mobility shift and supershift assays
Nuclear extracts were prepared as previously described [23]. Five lg
of nuclear extracts was used in the binding reaction with 35pmol of
labeled NF-jB oligonucleotide and 2 ll of 5· binding buﬀer (Pro-
mega). The oligonucleotide was labeled with c32-P in a reaction cata-
lyzed by the T4 polynucleotide kinase following the manufacturer’s
instructions. Positive controls were performed by using HeLa nuclear
extracts and competition assays were carried out to verify the speci-
ﬁcity of the probe by adding cold NF-jB probe (speciﬁc competitor) or
AP2 probe (non-speciﬁc competitor). The resulting protein–DNA
complexes were separated on a 5% polyacrylamide gel. The gel was
dried and exposed to an X-ray Hyperﬁlm MP at )70 C.
For supershift assays, 1 ll of antibody against p50 or p65 was in-
cubated with the nuclear extracts at room temperature for 30 min prior
addition of the labeled NF-jB probe.
2.5. Immunocytochemistry
Ten thousand cells were grown on sterile glass coverslips placed in a
24-well plate. After 48 h, cells were serum starved for 24 h and then
treated with 107 M of AM for 15 or 30 min in triplicate. Cells were
washed with PBS and ﬁxed with 3.5% paraformaldehyde for 15 min at
4 C. After washes with PBS, 1% Triton (v/v in PBS) was added for 5
min and then washed with PBS. Cells were incubated with blocking
buﬀer (10% FBS in PBS) for 30 min prior to overnight incubation with
1 lg/ml of primary antibody in either p50 or p65 made up in PBS with
1.5% FBS. Cells were washed and incubated with 1 lg/ml of secondary
antibody conjugated with Texas Red in PBS containing 3% FBS. After
several washes, nuclear staining was carried out by incubating cellswith 1:1000 DAPI in PBS for 5 min. Cells were washed again and the
coverslips were mounted cell side down onto Immu-Mount on fresh
slides. The coverslips were sealed and examined using a ﬂuorescence
microscope.3. Results
3.1. AM stimulates IjB degradation
In normal conditions, NF-jB is found in the cytoplasm of
cells as inactive form bound to its inhibitor IjB. After an in-
ﬂammatory stimulus IjB kinases (IKK) phosphorylates IjB,
which will be degraded releasing NF-jB that will be translo-
cated to the nucleus to induce transcription of genes involved
in the early onset of the inﬂammatory response. Western blot
analysis detected rapid degradation of IjBa only after 5 min of
treating the cells with 107 M AM (Fig. 1A). Shortly after, the
levels started to rise back reaching normal levels 2 h post-
stimulation. IjBb experienced a more discrete decrease after 5
min of treatment with AM (Fig. 1A), however, no statistical
diﬀerence was observed (Fig. 1B). Fig. 1B in the lower panel
quantiﬁes data pooled from 3 Western blot experiments.
3.2. AM stimulates the nuclear translocation of NF-jB subunits
p50 and p65
HaCaT cells were treated with 107 M AM for 15 or 30 min
and immunocytochemistry was performed to detect p50 and
p65, predominant members of the NF-jB family of tran-
scription factors. Fig. 2 illustrates that in non-stimulated cells
staining for p50 or p65 was located in the cytoplasm, whereas
after 15 min of treatment with AM the staining concentrated in
the nucleus of cells, indicating translocation of p50 and p65
(Fig. 2). Cells treated for 30 min did not show nuclear staining
in concordance with the fact that once the initial stimulus
Fig. 2. Immunostaining of p50 in HaCaT cells. (A) HaCaT cells were
stimulated with 107 M AM for 15 or 30 min and immunostained for
DAPI nuclear staining (upper panel) or p50 (lower panel). (B) Im-
munostaining for DAPI nuclear staining (upper panel) or p65 (lower
panel).
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thesized IjBs (Figs. 2 and 3).
Electrophoretic mobility shift assay using nuclear extracts
from HaCaT cells incubated with 107 M AM demonstrated
that the NF-jB detected in the nucleus by immunostaining was
indeed active, since it was capable of binding to a DNA oli-
goprobe containing an NF-jB binding site (Fig. 3A, upper
panel). The time course showed that the nucleus of non-treated
cells contained some basal levels of active NF-jB, but
the levels peaked between 10 and 15 min of AM treat-
ment followed by a steady decrease in activity (Fig. 3A upper
panel). The lower panel quantiﬁes data pooled from 3 such
experiments.
Supershift assays using antibodies against two of the most
common NF-jB family members, p50 and p65, were per-
formed to corroborate that both members were involved in
AM cell signaling. The addition of antibodies against p50 and
p65 created supershifts formed by antibody/NF-jB/probe, in-
dicating that p50 and p65 are part of the NF-jB dimmers
activated by AM (Fig. 3B upper panel).
3.3. AM stimulates IL-6 secretion from HaCaTs
HaCaT cells were treated with a range of AM concentra-
tions. Fig. 4 upper panel illustrates that AM caused a dose-
dependent increase in IL-6 secretion from these cells when
incubated in the presence of AM for 4 h. Signiﬁcant increases
in IL-5 production occurred at 1010 M AM and the eﬀect was
maximal at 107 M AM. Taking 108 M as the dose of AM to
give a maximal IL-6 response, the lower panel ﬁgure illustrates
the eﬀect of incubating the cells with this concentration for
increasing lengths of time. The ﬁgure shows that there was
signiﬁcant IL-6 secretion after a 30-min exposure to AM with
maximal production within 4 h.Fig. 5 illustrates the eﬀect of 108 M AM for 4 h in the
absence and presence of SN-50, an inhibitor of NF-jB. IL-6
levels were signiﬁcantly attenuated when AM-treated cells
were incubated in the presence of SN-50, a speciﬁc NF-jB
inhibitor.4. Discussion
The skin is the largest organ of the body and is continuous
with the mucous membranes lining the body’s oriﬁces. It exerts
a multitude of important functions mainly linked to dealing
with external physical, chemical and biological traumas. The
epidermis is a stratiﬁed epithelium and keratinocytes are the
principal cells providing both structural and functional roles to
skin. The skin was, until recently, regarded as a simple physical
barrier preventing bacterial invasion and the escape of body
ﬂuids. However, it is clear that the various cells found within
the epidermis, particularly keratinocytes, are highly dynamic
cells with the ability to react to changes within their environ-
ment. Keratinocytes can interact with other cells and are im-
portant during processes such as inﬂammation and wound
healing [24,25] and respond by secreting a range of growth
factors and cytokines [25,26]. However, keratinocytes have
received little attention in the world of immunology even
though the wide range of factors secreted by them have a
major role in processes such as proliferation, diﬀerentiation
and migration [27]. Studies from our laboratory, and others,
have demonstrated that AM stimulates proliferation of cul-
tured skin keratinocytes and that these cells express a func-
tional receptor for AM [6,10]. Recent studies by our group and
others have suggested that AM plays an important role as a
host defense peptide and inﬂammation [3–5,28].
AM is a 52 amino acid peptide with a disulﬁde bridge
originally extracted from a phaeochromocytoma and is part of
the calcitonin family of peptides [1]. AM has a wide tissue and
cell distribution and though it was initially described as a va-
sodilatory peptide, the current literature conﬁrms that AM has
many functions beyond vasoactivity. AM is also found in all
body ﬂuids studied so far. Studies by Caron’s group high-
lighted the importance of AM when it was reported that AM
knockout mice were embryonically lethal [29]. AM has now
been shown to have a role in proliferation, apoptosis, inhibi-
tion of salt appetite and water intake, host defense mecha-
nisms, increases in steroid and cytokine secretion [2–5,10].
We, and others, have reported that AM activates the cAMP
signaling pathway [14,30–34] and there are reports from others
demonstrating that AM can signal through other mechanisms
such as elevation of intracellular free Ca2þ [35–37]. However,
AM has been shown to have a regulatory eﬀect on growth and
mitogenesis by inhibiting mitogen-activated protein kinase
(MAPK) [33] and to be linked with K(ATP) channels through
CGRP1 receptor activation [38]. The major aim of this study
was to determine the role of AM and the NF-jB signaling
pathway. Gathered evidence indicates that AM is involved in
the regulation of inﬂammation and modiﬁes secretion of cy-
tokines such as IL-6, TNF-a and cytokine-induced neutrophil
chemoattractant [39–42]. NF-jB is a family of transcription
factors that play a crucial role in the activation of pro-
inﬂammatory genes and data from our laboratory and other
have provided evidence for an immunoregulatory role for AM
through the activation of NF-jB.
Fig. 3. Activation of NF-jB by AM. (A) Upper panel, the NF-jB probe was tested for its speciﬁcity by using no nuclear extract ()), HeLa nuclear
extracts (+), HeLa extracts and cold NF-jB probe (SC-speciﬁc competitor), or cold AP2 probe (NSC-non-speciﬁc competitor). The lanes represent
the shifts of HaCaT nuclear extracts obtained from a time course of treatment with 107 M AM for various lengths of time (in mins) or 10 ng/ml LPS
for 60 min. The arrow marks the shift generated by NF-jB bound to probe. Lower panel, quantiﬁcation of pooled data from three experiments.
(B) Upper panel, HaCaT cells were incubated with 107 M AM for 0, 30 or 90 min and nuclear protein extracted for testing the presence of p50 and
p65 in the NF-jB–DNA complex (supershift assay). HeLa nuclear extracts were used as a positive control. The arrows point at the immuno-
complexes generated by the addition of antibodies against p50 and p65. Lower panel, quantiﬁcation of pooled data from three experiments; open
bars, NF-jB; gray bars, p65; ﬁlled bars, p50 levels. Values are meansS.E.M., n ¼ 3. *P < 0:05, **P < 0:01, ***P < 0:001 compared to 0 (no
treatment; analysis of variance and Tukey’s multiple comparison test).
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are also pleiotropic regulators of cellular growth and homeo-
stasis [43]. Recently, NF-jB was also implicated as a pivotal
regulator of epidermal proliferation and diﬀerentiation for
reviews see [44,45], even though the precise function of NF-jB
in epidermal homeostasis remains enigmatic. Some emergingstudies have suggested that NF-jB has a protective role in
premature apoptosis [46,47].
In normal conditions, NF-jB is found in the cytoplasm of
cells bound to its inhibitor (IjB). Several stimuli, such as pro-
inﬂammatory cytokines and bacterial infection trigger activa-
tion of IKK that will phosphorylate NF-jB inhibitors. This
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Fig. 4. Eﬀect of AM and time on IL-6 secretion. Upper panel, cells
were incubated with increasing concentrations of AM. Lower panel,
cells were incubated with 108 M AM for increasing lengths of time.
Values are means S.E.M., n ¼ 3. *P < 0:05, **P < 0:01,
***P < 0:001 compared to basal (ANOVA and Tukey’s multiple
comparison test).
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Fig. 5. Measurement of IL-6 secretion from HaCaT cells. Cells were
incubated for 4 h with control or 108 M AM in the absence (empty
bars) and presence of 105 M SN-50 (ﬁlled bars), an NF-jB inhibitor.
Values are meansS.E.M., n ¼ 3. *P < 0:05 compared to control
(ANOVA and Tukey’s multiple comparison test), þP < 0:05 compared
to AM-stimulated IL-6 levels (Student’s t test).
O. Pleguezuelos et al. / FEBS Letters 577 (2004) 249–254 253step will release NF-jB, which will be translocated into the
nucleus where it will bind to NF-jB binding sites in the pro-
moter of certain genes inducing their transcription. Once IjB is
phosphorylated, it will be ubiquitinized and degraded (hence,
measurement of IjB degradation is a good indication of NF-
jB activation). Several groups questioned the need for two
NF-jB inhibitors, IjBa and IjBb, and that led to a search for
any diﬀerences in their degradation pattern. IjBa is degraded
by all known inducers of NF-jB as opposed to IjBb being
degraded by stimuli that cause persistent activation of NF-jB,such as IL-1 and LPS. However in cases of persistent activa-
tion, once the original pool of IjBb is degraded, new IjBb is
synthesized with an altered conformation and binds to NF-jB
not to inhibit it but to protect it from IjBa inhibition. NF-jB
bound to IjBb is still active and capable of inducing gene
transcription [48]. IjBa and IjBb also play diﬀerent roles in
apoptosis in mice pre-B-cells. Research showed that the ap-
optotic drug 3-CPA inhibited the degradation of IjBa,
whereas the anti-apoptotic drug Na-3-CPA inhibited degra-
dation of IjBb [49]. These indicate that both inhibitors have
distinct roles in the regulation of various NF-jB activities.
Combining the results obtained, it can be concluded that
NF-jB is involved in the AM cell signaling. Degradation of
IBs was observed after 5 min of treatment with AM. IjBa
degradation was noticeably higher than IjBb degradation,
indicating that AM does not induce a persistent activation of
NF-jB as required by either IL-1 or LPS. The steady decrease
in IjBs corresponds in time with the detection by immuno-
staining of free translocated NF-jB in the nuclei of cells. The
nuclear staining decreases after 30 min of treatment with AM
and the staining returns to the cytoplasm, indicating that nu-
clear NF-jB has been sequestered by the newly synthesized
IjBs and transported back to the cytoplasm.
Electromobility shift assays showed that the nuclear NF-jB
detected in the cells by immunostaining was active and ca-
pable of binding to NF-jB binding sites in the DNA within
30 min. NF-jB consists of homo- or heterodimers of the
diﬀerent members of the family (p65, c-Rel, RelB, p50/p105,
and p52/p100). P50 and p65 are the predominant proteins in
the NF-jB complex, so to assess whether their activation was
induced by AM, antibodies against them were incubated with
nuclear protein extracts and NF-jB probe. Supershifts were
observed when antibodies against p50 and p65 were used,
indicating the presence of both members in the NF-jB
complex activated by AM treatment in HaCaT cells. These
supershift assays were not carried out at 10 min, however, it
should be noted that degradation of IjBa and IjBb occur-
ring, as measured within 30 min, does not exclude the sub-
sequentNF-jB subunits binding to the regulatory elements
during this time.
Binding of NF-jB to promoter sequences induces tran-
scription of genes involved in the early onset of the inﬂam-
matory response. Several pro-inﬂammatory cytokines (TNF-a,
IL-1a, IL-6, etc.) are synthesized and secreted as a result. We
measured the secretion of IL-6 after treatment with AM, as an
indication of its inﬂammatory role, and a signiﬁcant increase
was observed in HaCaT cells, suggesting an immunomodula-
tory role for AM in these cells. Other studies in HaCaT cells
challenged with bacteria or LPS showed no secretion of IL-6,
IL-1 or TNF-a compared to the controls, but showed in-
creased expression of MHC class II [50], however that may
have been inﬂuenced by cell density, since cytokine synthe-
sis and secretion by HaCaT cells increases when cells are
proliferating [51].
To conclude, we have shown that AM induces degradation
of IjBs and as a result, NF-jB (p50/p65) is translocated to the
nucleus of HaCaT cells where it will induce expression of genes
such as IL-6. There are several aspects of the AM signaling
through NF-jB that are yet to be understood, such as the
diﬀerential involvement of IjBa and IjBb and their kinases
IKKa and IKKb and what genes are up or downregulated as a
consequence of NF-jB activation.
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